SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

29 Oct 2021 Evaluate
The revenue for the September 2021 quarter is pegged at Rs. 8237.10 millions, about 21.76% up against Rs. 6765.10 millions recorded during the year-ago period.The Net Profit of the company registered a slight decline of -12.60% to Rs. 1968.50  millions from Rs. 2252.20 millions.The company reported a degrowth in operating Profit to 2852.60 millions from 3370.80 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202109 202009 % Var 202109 202009 % Var 202103 202003 % Var
Sales 8237.10 6765.10 21.76 15664.30 12373.60 26.59 27185.90 21964.20 23.77
Other Income 524.10 862.40 -39.23 834.10 993.40 -16.04 1035.70 1842.00 -43.77
PBIDT 2852.60 3370.80 -15.37 5492.80 5236.10 4.90 10204.80 7169.80 42.33
Interest 0.70 13.50 -94.81 12.40 25.50 -51.37 69.00 91.00 -24.18
PBDT 2851.90 3357.30 -15.05 5480.40 5210.60 5.18 10135.80 7039.60 43.98
Depreciation 304.00 272.00 11.76 601.60 540.60 11.28 1114.90 912.90 22.13
PBT 2547.90 3085.30 -17.42 4878.80 4670.00 4.47 9020.90 6126.70 47.24
TAX 579.40 833.10 -30.45 975.70 1260.90 -22.62 2264.50 1715.40 32.01
Deferred Tax 30.80 91.60 -66.38 63.40 138.70 -54.29 97.70 34.50 183.19
PAT 1968.50 2252.20 -12.60 3903.10 3409.10 14.49 6756.40 4411.30 53.16
Equity 173.90 175.40 -0.86 173.90 175.40 -0.86 173.90 175.40 -0.86
PBIDTM(%) 34.63 49.83 -30.50 35.07 42.32 -17.14 37.54 32.64 14.99

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×